Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.55 |
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.53 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.53 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.42 |
| ▸ | PPARG | P37231 | 6/20 | 0.42 |
| ▸ | PPARD | Q03181 | 6/20 | 0.42 |
| ▸ | PPARA | Q07869 | 6/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL50511 | 0.81 | FFAR3 (0.77) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Succinic Acid SCHEMBL28184121 | 0.77 | LMNA (0.75) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| SCHEMBL108375 | 0.77 | — | — | |
| SCHEMBL27892113 | 0.76 | EGLN1 (0.45) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Succinic Acid SCHEMBL143984 | 0.75 | FFAR3 (0.67) | EGLN1OR51E2LMNAALKBH5SUCNR1 | |
| SCHEMBL105956 | 0.75 | — | — | |
| Succinic Acid SCHEMBL6417713 | 0.75 | LMNA (0.71) | EGLN1OR51E2LMNAALKBH5SUCNR1 | |
| Succinic Acid SCHEMBL7568310 | 0.74 | LMNA (0.50) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Succinic Acid SCHEMBL80940 | 0.74 | LMNA (0.69) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Succinic Acid SCHEMBL2363993 | 0.74 | FFAR3 (0.73) | EGLN1OR51E2LMNAALKBH5SUCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196073-B2 | Imine-forming polysaccharide adjuvants and immunostimulants | ADJUVANTYS, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-6960344-B2 | Use of imine-forming polysaccharides as adjuvants and immunostimulants | GALENICA PHARMACEUTICALS, INC. (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1574217-A1 | Imine-forming polysaccharides, preparation thereof and the use thereof as adjuvants and immunostimulants | Galenica Pharmaceuticals, Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1027061-B1 | IMINE-FORMING POLYSACCHARIDES, PREPARATION THEREOF AND THE USE THEREOF AS ADJUVANTS AND IMMUNOSTIMULANTS | GALENICA PHARMACEUTICALS INC (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040220142-A1 | Imine-forming polysaccharide adjuvants and immunostimulants | GALENICA PHARMACEUTICALS, INC. | 2004-11-04 | — | — | US | disclosed |
| US-20020150585-A1 | Use of imine-forming polysaccharides as adjuvants and immunostimulants | GALENICA PHARMACEUTICALS, INC. | 2002-10-17 | — | — | US | disclosed |
| EP-1027061-A4 | IMINE-FORMING POLYSACCHARIDES, PREPARATION THEREOF AND THE USE THEREOF AS ADJUVANTS AND IMMUNOSTIMULANTS | GALENICA PHARMACEUTICALS INC (US) | 2000-12-13 | — | — | EP | disclosed |
| EP-1027061-A1 | IMINE-FORMING POLYSACCHARIDES, PREPARATION THEREOF AND THE USE THEREOF AS ADJUVANTS AND IMMUNOSTIMULANTS | Galenica Pharmaceuticals, Inc. (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999017783-A1 | IMINE-FORMING POLYSACCHARIDES, PREPARATION THEREOF AND THE USE THEREOF AS ADJUVANTS AND IMMUNOSTIMULANTS | GALENICA PHARMACEUTICALS, INC. (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220142-A1 | Imine-forming polysaccharide adjuvants and immunostimulants | TLR1, TLR2, TLR9 | EGLN1 3910/4885OR51E2 2575/4885MAPK1 937/4885 |
| US-20020150585-A1 | Use of imine-forming polysaccharides as adjuvants and immunostimulants | TLR1, ICOS, TLR2 | EGLN1 3847/4885OR51E2 2590/4885MAPK1 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.